Osteoporosis Is a Toxic Effect of Long-term Etretinate Therapy

Archives of Dermatology

Volumn 131, Issue 11, 1995, Pages 1263-1267

  Digiovanna, John J ^a,c   Sollitto, Robert B ^a   Abangan, Donita L ^a,d   Steinberg, Seth M ^a   Reynolds, James C ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d KING DREW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIFICATION; CLINICAL ARTICLE; DEMINERALIZATION; FEMALE; HISTIOCYTOMA; HUMAN; ICHTHYOSIS; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; SKIN CANCER; XERODERMA PIGMENTOSUM;

ADULT; AGED; BONE DENSITY; CROSS-SECTIONAL STUDIES; ETRETINATE; FEMALE; HUMAN; ISOTRETINOIN; KERATOLYTIC AGENTS; MALE; MIDDLE AGE; OSTEOPOROSIS; TIME FACTORS;

EID: 0028784302     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1995.01690230041007     Document Type: Article

References (33)

1. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosa with the use of oral etretinate. N Engl J Med. 1988; 3: 1633-1637.
2. Peck GL, DiGiovanna JJ. Retinoids. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg, IM, Austen KF, eds. Dermatology in General Medicine. 4th ed. New York, NY: McGraw-Hill International Book Co; 1993: 2883-2908.
3. DiGiovanna JJ. Retinoids for the future: oncology. J Am Acad Dermatol. 1992; 27: S34-S37.
4. Milstone L, McGuire J, Ablow R. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol. 1982; 7: 663-666.
5. Pittsley RA, Yoder FW. Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med. 1983; 308: 1012-1014.
6. Gerber LH, Helfgott RK, Gross EG, Hicks JE, Ellenberg SS, Peck GL. Vertebral abnormalities associated with synthetic retinoid use. J Am Acad Dermatol. 1984; 10: 817-823.
7. DiGiovanna JJ, Peck GL. Retinoid toxicity. Prog Dermatol. 1987; 21: 1-7.
8. DiGiovanna JJ, Helfgott R, Gerber LH, Peck GL. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med. 1986; 315: 1177-1182.
9. Fell HB, Mellanby E. Effects of hypervitaminosis A on foetal mouse bones cultivated in vitro. BMJ. 1950; 2: 535-539.
10. Wolbach SB. Vitamin-A deficiency and excess in relation to skeletal growth. J Bone Joint Surg. 1947; 29: 171-192.
11. Collaxo JA, Rodriguez JS. Hypervitaminosis A. Klin Wochenschr. 1933; 12: 1732-1734.
12. Bartolozzi G, Bernini G. Chronic hypervitaminosis A. Helv Paediatr Acta. 1970; 25: 301-304.
13. Frame B, Jackson CE, Reynolds WA, Umphrey JE. Hypercalcemia and skeletal effects in chronic hypervitaminosis A. Ann Intern Med. 1974; 80: 44-48.
14. McGuire J, Lawson JP. Skeletal changes associated with chronic isotretinoin and etretinate administration. Dermatologica. 1987; 175: 169-181.
15. Ruiz-Maldonado R, Tamayo L. Retinoids in disorders of keratinization: their use in children. Dermatologica. 1987; 175(suppl 1): 125-132.
16. Halkier-Sørensen L, Andersen J. A retrospective study of bone changes in adults treated with etretinate. J Am Acad Dermatol. 1989; 20: 83-87.
17. Okada N, Nomura M, Morimoto S, Ogihara T, Yoshikawa K. Bone mineral density of the lumbar spine in psoriatic patients with long-term etretinate therapy. J Dermatol. 1994; 21: 308-311.
18. Brun P, Baran R. Neonatal ichthyosis treated for seven years with etretinate without effects on growth or ossification: a case report. Curr Ther Res. 1986; 40: 657-663.
19. Gilbert M, Ellis CN, Voorhees JJ. Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis. Dermatologica. 1986; 172: 160-163.
20. Glover MT, Peters AM, Atherton DJ. Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol. 1987; 116: 609-614.
21. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol. 1987; 16: 267-291.
22. Margolis DJ. The effects of isotretinoin on the axial skeleton and the retinoid effect. Arch Dermatol. 1992; 128: 1650.
23. Milstone LM, Insogna KL. The effects of isotretinoin on the axial skeleton and the retinoid effect. Arch Dermatol. 1992; 128: 1650.
24. Kannel WB, Sorlie MS. Some benefits of physical activity. Arch Intern Med. 1979; 139: 857-861.
25. Ghosh L, West DP, Weiss VC, Ronan S, Buys CM. Bone effects of retinoids (isotretinoin and etretinate) in albino hairless mice. Clin Res. 1985; 33: 640A. Abstract.
26. Teelmann K. Experimental toxicology of the aromatic retinoid Ro 10-9359 (etretinate). In: Orfanos CE, Braun-Falco 0, Farber EM, Grupper Ch, Polano MK, Schuppli R, eds. Retinoids: Advances in Basic Research and Therapy. New York, NY: Springer-Verlag NY Inc; 1981: 41-47.
27. DiGiovanna JJ, Zech LA, Ruddell ME, Gantt G, Peck GL. Etretinate: persistent serum levels after long-term therapy. Arch Dermatol. 1989; 125: 246-251.
28. Kaiser-Kupfer MI, Peck GL, Caruso RC, Jaffee MJ, DiGiovanna JJ, Gross EG. Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol. 1986; 104: 69-70.
29. Hixon EJ, Denine EP. Comparative subacute toxicity of all-trans- and 13-cis-retinoic acid in Swiss mice. Toxicol Appl Pharmacol. 1978; 44: 29-40.
30. Maiorana A, Gullino PM. Effect of retinyl acetate on the incidence of mammary carcinomas and hepatomas in mice. J Natl Cancer Inst. 1980; 64: 655-663.
31. Kilcoyne RF, Cope R, Cunningham WJ, et al. Minimal spinal hyperostosis with low-dose isotretinoin therapy. Invest Radiol. 1986; 21: 41-44.
32. Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ III. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981; 67: 328-335.
33. Carlberg C, Bendik I, Wyss A, et al. Two nuclear signaling pathways for vitamin D. Nature. 1993; 361: 657-660.